• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023.临床流行病学和接种与未接种 COVID-19 住院成年人重症结局的危险因素-VISION 网络,10 个州,2021 年 6 月至 2023 年 3 月。
Clin Infect Dis. 2024 Feb 17;78(2):338-348. doi: 10.1093/cid/ciad505.
2
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.2021 年 1 月至 2022 年 4 月,13 个美国州 18 岁及以上接种和未接种疫苗的成年人因 COVID-19 住院的情况。
JAMA Intern Med. 2022 Oct 1;182(10):1071-1081. doi: 10.1001/jamainternmed.2022.4299.
3
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.COVID-19 病例和住院情况按 COVID-19 疫苗接种状况和既往 COVID-19 诊断情况划分-加利福尼亚州和纽约州,2021 年 5 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1.
4
Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021.成人因实验室确诊的 COVID-19 住院的严重程度在 SARS-CoV-2 B.1.617.2(Delta)流行之前和期间-COVID-NET,14 个州,2021 年 1 月至 8 月。
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1513-1519. doi: 10.15585/mmwr.mm7043e1.
5
COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People.接种疫苗和未接种疫苗人群中的 COVID-19 和精神疾病。
JAMA Psychiatry. 2024 Nov 1;81(11):1071-1080. doi: 10.1001/jamapsychiatry.2024.2339.
6
Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy.意大利伦巴第地区 COVID-19 疫苗接种与入住重症监护病房以及 COVID-19 肺炎重症患者结局的相关性。
JAMA Netw Open. 2022 Oct 3;5(10):e2238871. doi: 10.1001/jamanetworkopen.2022.38871.
7
Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022.在 SARS-CoV-2 奥密克戎 BA.2 变异株流行期间,实验室确诊的 COVID-19 相关住院病例:COVID-19 相关住院监测网络,14 个州,2021 年 6 月 20 日-2022 年 5 月 31 日。
MMWR Morb Mortal Wkly Rep. 2022 Aug 26;71(34):1085-1091. doi: 10.15585/mmwr.mm7134a3.
8
SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.2021 年 5 月 1 日至 7 月 25 日,加利福尼亚州洛杉矶县≥16 岁人群中,根据疫苗接种状况划分的 SARS-CoV-2 感染和住院情况。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.
9
Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022.保护两剂和三剂 mRNA 疫苗对 COVID-19-VISION 网络中住院成人严重结局的影响,2021 年 8 月至 2022 年 3 月。
J Infect Dis. 2023 Apr 18;227(8):961-969. doi: 10.1093/infdis/jiac458.
10
Comprehensive statistical analysis reveals significant benefits of COVID-19 vaccination in hospitalized patients: propensity score, covariate adjustment, and feature importance by permutation.综合统计分析显示,COVID-19 疫苗接种对住院患者具有显著益处:倾向评分、协变量调整和通过置换的特征重要性。
BMC Infect Dis. 2024 Sep 27;24(1):1052. doi: 10.1186/s12879-024-09865-1.

引用本文的文献

1
SARS-CoV-2 uptake and inflammatory response in senescent endothelial cells are regulated by the BSG/VEGFR2 pathway.衰老内皮细胞中SARS-CoV-2的摄取和炎症反应受BSG/VEGFR2途径调控。
Proc Natl Acad Sci U S A. 2025 Aug 5;122(31):e2502724122. doi: 10.1073/pnas.2502724122. Epub 2025 Jul 28.
2
A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?一项关于瑞德西韦治疗住院的2019冠状病毒病患者有效性的系统评价和荟萃分析:指南是否随着证据的变化而演变?
Clin Infect Dis. 2025 Aug 1;81(1):20-29. doi: 10.1093/cid/ciaf111.
3
An exploration of the natural and acquired immunological mechanisms to high-risk human papillomavirus infection and unmasking immune escape in cervical cancer: A concise synopsis.高危型人乳头瘤病毒感染的天然和获得性免疫机制及宫颈癌免疫逃逸揭秘探索:简要概述
Tzu Chi Med J. 2024 Dec 3;37(1):28-41. doi: 10.4103/tcmj.tcmj_134_24. eCollection 2025 Jan-Mar.
4
Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial.福斯他替尼用于治疗住院的新冠肺炎低氧血症成人患者:一项随机临床试验。
JAMA Netw Open. 2024 Dec 2;7(12):e2448215. doi: 10.1001/jamanetworkopen.2024.48215.
5
Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022-August 2023.原始单价和二价新冠疫苗对未免疫功能低下的孕妇新冠相关急诊科和紧急护理就诊的有效性:VISION网络,2022年6月至2023年8月
Open Forum Infect Dis. 2024 Aug 28;11(9):ofae481. doi: 10.1093/ofid/ofae481. eCollection 2024 Sep.
6
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates.黏膜型腺病毒疫苗加强免疫可诱导 IgA 产生,并可持久预防非人灵长类动物感染 XBB.1.16。
Nat Immunol. 2024 Oct;25(10):1913-1927. doi: 10.1038/s41590-024-01951-5. Epub 2024 Sep 3.
7
SARS-CoV-2 Variants and Clinical Outcomes of Special Populations: A Scoping Review of the Literature.SARS-CoV-2 变异株和特殊人群的临床结局:文献的范围综述。
Viruses. 2024 Jul 30;16(8):1222. doi: 10.3390/v16081222.
8
Vaccination in Patients with Liver Cirrhosis: A Neglected Topic.肝硬化患者的疫苗接种:一个被忽视的话题。
Vaccines (Basel). 2024 Jun 27;12(7):715. doi: 10.3390/vaccines12070715.
9
High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4 and CD8 memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients.高频率的α型普通感冒冠状病毒/SARS-CoV-2 交叉反应性功能性 CD4 和 CD8 记忆 T 细胞与未接种疫苗的 COVID-19 患者免受有症状和致命 SARS-CoV-2 感染有关。
Front Immunol. 2024 Mar 28;15:1343716. doi: 10.3389/fimmu.2024.1343716. eCollection 2024.
10
COVID-19: On the threshold of the fifth year. The situation in Spain.新冠疫情:步入第五年。西班牙的情况。
Rev Esp Quimioter. 2024 Feb;37(1):17-28. doi: 10.37201/req/123.2023. Epub 2023 Nov 27.

本文引用的文献

1
Relationships Between Social Vulnerability and Coronavirus Disease 2019 Vaccination Coverage and Vaccine Effectiveness.社会脆弱性与 2019 年冠状病毒病疫苗接种覆盖率和疫苗有效性之间的关系。
Clin Infect Dis. 2023 May 3;76(9):1615-1625. doi: 10.1093/cid/ciad003.
2
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.2022 年 9 月至 11 月,免疫功能正常的成年人中,二价 mRNA 疫苗在预防 COVID-19 相关急诊或紧急护理就诊和住院方面的早期效果估计 - VISION 网络,九个州。
MMWR Morb Mortal Wkly Rep. 2022 Dec 30;71(5152):1616-1624. doi: 10.15585/mmwr.mm715152e1.
3
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.免疫实践咨询委员会关于使用二价加强针 COVID-19 疫苗的临时建议-美国,2022 年 10 月。
MMWR Morb Mortal Wkly Rep. 2022 Nov 11;71(45):1436-1441. doi: 10.15585/mmwr.mm7145a2.
4
Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.新英格兰地区估计 SARS-CoV-2 奥密克戎 BA.2 亚变种的严重程度。
JAMA Netw Open. 2022 Oct 3;5(10):e2238354. doi: 10.1001/jamanetworkopen.2022.38354.
5
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.COVID-19 mRNA 疫苗在奥密克戎为主导期间对免疫功能低下成年人 COVID-19 相关住院的有效性- VISION 网络,10 个州,2021 年 12 月至 2022 年 8 月。
MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1335-1342. doi: 10.15585/mmwr.mm7142a4.
6
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study.针对美国与 COVID-19 相关住院的初级系列和加强剂量疫苗有效性:基于阴性设计的实时研究。
BMJ. 2022 Oct 11;379:e072065. doi: 10.1136/bmj-2022-072065.
7
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.SARS-CoV-2 奥密克戎 BA.5:与关注的病毒变体相比,其对潜在体液反应的趋化性和逃逸能力以及对临床免疫疗法的耐药性不断进化。
EBioMedicine. 2022 Oct;84:104270. doi: 10.1016/j.ebiom.2022.104270. Epub 2022 Sep 18.
8
Severity of COVID-19 cases in the months of predominance of the Alpha and Delta variants.新冠病毒 Alpha 和 Delta 变异株流行期间病例严重程度。
Sci Rep. 2022 Sep 14;12(1):15456. doi: 10.1038/s41598-022-19125-4.
9
Evaluation of Risk Factors for Postbooster Omicron COVID-19 Deaths in England.评估英格兰奥密克戎 COVID-19 加强针后死亡的风险因素。
JAMA Netw Open. 2022 Sep 1;5(9):e2233446. doi: 10.1001/jamanetworkopen.2022.33446.
10
Infection with the Omicron variant of SARS-CoV-2 is associated with less severe disease in hospitalized patients with COVID-19.感染新冠病毒奥密克戎变异株与新冠肺炎住院患者病情较轻有关。
J Infect. 2022 Nov;85(5):e152-e154. doi: 10.1016/j.jinf.2022.07.029. Epub 2022 Aug 6.

临床流行病学和接种与未接种 COVID-19 住院成年人重症结局的危险因素-VISION 网络,10 个州,2021 年 6 月至 2023 年 3 月。

Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023.

机构信息

Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Department of Clinical Research, Westat, Inc, Rockville, Maryland, USA.

出版信息

Clin Infect Dis. 2024 Feb 17;78(2):338-348. doi: 10.1093/cid/ciad505.

DOI:10.1093/cid/ciad505
PMID:37633258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11293024/
Abstract

BACKGROUND

The epidemiology of coronavirus disease 2019 (COVID-19) continues to develop with emerging variants, expanding population-level immunity, and advances in clinical care. We describe changes in the clinical epidemiology of COVID-19 hospitalizations and risk factors for critical outcomes over time.

METHODS

We included adults aged ≥18 years from 10 states hospitalized with COVID-19 June 2021-March 2023. We evaluated changes in demographics, clinical characteristics, and critical outcomes (intensive care unit admission and/or death) and evaluated critical outcomes risk factors (risk ratios [RRs]), stratified by COVID-19 vaccination status.

RESULTS

A total of 60 488 COVID-19-associated hospitalizations were included in the analysis. Among those hospitalized, median age increased from 60 to 75 years, proportion vaccinated increased from 18.2% to 70.1%, and critical outcomes declined from 24.8% to 19.4% (all P < .001) between the Delta (June-December, 2021) and post-BA.4/BA.5 (September 2022-March 2023) periods. Hospitalization events with critical outcomes had a higher proportion of ≥4 categories of medical condition categories assessed (32.8%) compared to all hospitalizations (23.0%). Critical outcome risk factors were similar for unvaccinated and vaccinated populations; presence of ≥4 medical condition categories was most strongly associated with risk of critical outcomes regardless of vaccine status (unvaccinated: adjusted RR, 2.27 [95% confidence interval {CI}, 2.14-2.41]; vaccinated: adjusted RR, 1.73 [95% CI, 1.56-1.92]) across periods.

CONCLUSIONS

The proportion of adults hospitalized with COVID-19 who experienced critical outcomes decreased with time, and median patient age increased with time. Multimorbidity was most strongly associated with critical outcomes.

摘要

背景

随着新出现的变异株、人群免疫水平的提高以及临床治疗的进步,2019 年冠状病毒病(COVID-19)的流行病学仍在不断发展。我们描述了 COVID-19 住院患者的临床流行病学变化以及与重症结局相关的危险因素随时间的变化。

方法

我们纳入了 2021 年 6 月至 2023 年 3 月期间来自 10 个州因 COVID-19 住院的年龄≥18 岁的成年人。我们评估了人口统计学、临床特征和重症结局(入住重症监护病房和/或死亡)的变化,并评估了 COVID-19 疫苗接种状态分层后的重症结局危险因素(风险比[RR])。

结果

共纳入 60488 例 COVID-19 相关住院患者进行分析。与住院相关的患者中,年龄中位数从 60 岁增加到 75 岁,接种疫苗的比例从 18.2%增加到 70.1%,重症结局从 24.8%下降到 19.4%(所有 P 值均<.001),从 Delta 变异株(2021 年 6 月至 12 月)到 BA.4/BA.5 变异株(2022 年 9 月至 2023 年 3 月)流行期间。有重症结局的住院事件中,有≥4 个类别的医疗状况评估类别(32.8%)的比例高于所有住院患者(23.0%)。未接种疫苗和接种疫苗的人群中,重症结局的危险因素相似;无论疫苗状态如何,存在≥4 种医疗状况类别与重症结局风险的相关性最强(未接种疫苗:调整后的 RR,2.27[95%置信区间{CI},2.14-2.41];接种疫苗:调整后的 RR,1.73[95% CI,1.56-1.92])。

结论

随着时间的推移,COVID-19 住院患者中经历重症结局的成年人比例下降,患者的中位年龄随时间推移而增加。合并症与重症结局的相关性最强。